Saturday, March 07, 2026

In Detail Full day, Saturday, March 07, 2026, Timezone: America/Chicago

Eli Lilly's new program aims to boost employer coverage of GLP-1s

Shelby Livingston / endpoints - With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers' GLP-1 treatments. The pharma giant on Thursday announced the launch of ...

AI Summary: Eli Lilly unveiled an Employer Connect program designed to help employers expand coverage for GLP‑1–class weight‑loss drugs amid stalled insurer uptake. The initiative offers new contracting and access pathways for workplaces, addressing demand while prompting debate over whether it changes the underlying benefit‑design economics. It’s helpful—if you don’t expect a revolution.

Patients with multiple chronic diseases are a looming threat to health systems' financials: Vizient

fiercehealthcare - A recent claims data analysis shows the 11% of people with multiple chronic conditions are behind 52% of inpatient admissions and about a third of outpatient visits. Their projected increases and unfavorable payer mix spell trouble for health systems' bot…

AI Summary: A Vizient analysis shows roughly 11% of the U.S. population accounts for about 52% of hospital admissions, spotlighting how patients with multiple chronic conditions consume disproportionate inpatient resources. The report warns this concentration strains hospital finances and operational capacity, and calls for targeted care models to manage high‑need populations more efficiently.

How springing forward to daylight saving time could affect your health

medicalxpress - Most of America "springs forward" Sunday for daylight saving time. Losing that hour of sleep can do more than leave you tired and cranky the next day; it also could harm your health.

AI Summary: The clock change that robs people of an hour of sleep is back, and so are the predictable health hiccups: disrupted circadian rhythm, deeper sleep loss and more migraine flare‑ups. Experts warn even a single lost hour can nudge vulnerable people toward worse sleep, mood and short‑term cardiovascular risk — so yes, your crankiness is data‑backed.

Elizabeth McKenna: New Cancer Grand Challenges Teams Announced

oncodaily - Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: “The new Cancer Grand Challenges teams have just been announced! Read about the teams tackling cancer avoidance, mechanisms […]

AI Summary: Global funders announced new Cancer Grand Challenges awards, backing five international teams with large, high‑risk grants to pursue transformative cancer science. The initiative aims to accelerate unconventional, high‑reward projects and foster cross‑disciplinary collaboration — essentially underwriting audacity in hopes that at least one risky bet pays off.

ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS

oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]

AI Summary: At ASCO GU, investigators showcased belzutifan‑based combinations for renal cell carcinoma, including belzutifan with lenvatinib and perioperative belzutifan plus pembrolizumab. Data presented indicate these HIF‑2α‑targeted regimens can extend disease‑free intervals in high‑risk clear‑cell RCC, prompting interest in integrating hypoxia‑axis inhibitors into multimodal kidney‑cancer care.

CART19-BE-02 trial: From Bench to Bedside and Beyond – Resonance

oncodaily - ALRCaN presents “CART19-BE-02 trial: From Bench to Bedside and Beyond—Implementing a Hospital-Based CAR T Program and Integrating It into the Spanish NHS” with Dr. Valentín Ortiz-Maldonado. “Dear friends and colleagues, […]

AI Summary: Bereaved relatives delivered searing final testimonies as the Covid inquiry wound up four years of public hearings, recounting loved ones who died alone and demanding answers. Chair Baroness Heather Hallett defended the process and its roughly £200 million price tag as necessary to finish the work, despite public frustration and political scrutiny.

Telehealth growth hasn’t increased rural behavioral healthcare access: Study

Giles Bruce / beckershospitalreview - The rise in telemedicine over the past several years hasn’t translated to more behavioral healthcare access in rural areas, according to a March 5 study in JAMA Network Open. Researchers from Boston-based Harvard Medical School and Providence, R.I.-based …

AI Summary: A new study finds the rapid expansion of telemedicine did not meaningfully improve access to behavioral health services in rural areas. Persistent barriers—workforce shortages, broadband gaps, and reimbursement limits—keep telehealth from being the miracle fix some hoped for. Turns out, high-speed internet isn’t a therapist.

CVS Health, Google Cloud to launch healthcare engagement platform

Naomi Diaz / beckershospitalreview - CVS Health is partnering with Google Cloud to develop an AI-powered consumer engagement platform as part of a broader effort to reshape how patients interact with the healthcare system. In a March 5 news release, the company announced a partnership with G…

AI Summary: CVS Health and Google Cloud are teaming up to build Health100, an AI-driven consumer engagement platform designed to aggregate patient data and surface personalized care recommendations. The collaboration aims to streamline access, coordinate care, and power new digital services—because if your fridge can order milk, it should at least help you book a doctor.

New AI tool predicts best pancreatic cancer treatment

medicalxpress - A new tool co-developed by investigators from Cedars-Sinai Health Sciences University can predict which of two available chemotherapy options for pancreatic cancer would be more effective for an individual patient.

AI Summary: A Cedars‑Sinai–developed AI platform predicts which of two standard chemotherapy regimens will best suit individual pancreatic cancer patients. The model analyzes clinical and molecular data to guide therapy selection, aiming to personalize treatment and improve outcomes in a disease notorious for poor prognosis—because guesswork is overrated when lives are at stake.

FDA lifts hold on Intellia trial

Ella Jeffries / beckershospitalreview - The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver transaminase elevations and elevated bilirubin following a Sept. 3…

AI Summary: The FDA has lifted clinical holds on Intellia Therapeutics’ Phase 3 gene‑editing trials, allowing the company to resume patient enrollment and advance its nexiguran (nex‑z) development program. Regulators appear satisfied with submitted safety updates, clearing a major regulatory hurdle and moving the gene-editing program back toward its clinical milestones.

Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma

Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…

AI Summary: Servier is buying Day One Biopharmaceuticals for about $2.5 billion to bolster its rare oncology portfolio, gaining access to promising targeted therapies. The deal expands Servier’s presence in specialty cancer medicines and aligns with its strategic push into rare tumors, with integration and regulatory steps expected to follow.